Journal
ENDOCRINE-RELATED CANCER
Volume 22, Issue 3, Pages R87-R106Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-14-0543
Keywords
androgen receptor; hormone receptor; breast cancer; prostate cancer
Categories
Funding
- Medivation
- Janssen
- AstraZeneca
- Bayer
- Sanofi Aventis
Ask authors/readers for more resources
Prostate cancer (PCa) and breast cancer (BCa) share similarities as hormone-sensitive cancers with a wide heterogeneity of both phenotype and biology. The androgen receptor (AR) is a hormone receptor involved in both benign and malignant processes. Targeting androgen synthesis and the AR pathway has been and remains central to PCa therapy. Recently, there has been increased interest in the role of the AR in BCa development and growth, with results indicating AR co-expression with estrogen, progesterone, and human epidermal growth factor receptors, across all intrinsic subtypes of BCa. Targeting the AR axis is an evolving field with novel therapies in development which may ultimately be applicable to both tumor types. In this review, we offer an overview of available agents which target the AR axis in both PCa and BCa and provide insights into the novel drugs in development for targeting this signaling pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available